MIMEDX GROUP, INC. (MDXG) presents a structurally positive liquidation posture for Q1 2026, driven by a dominant cash position, but the recovery picture has deteriorated materially from the prior year period following a severe Medicare reimbursement shock to the Wound Care segment. Under liquidation lens at March 31, 2026: total assets of $308.7M face total liabilities of $65.7M at face value, producing GAAP book equity of $243.0M. After applying standard recovery haircuts—cash at 100% ($159.8M), net AR at 90-95% (~$43.7M on $46.0M net book), inventory at 60% (~$15.7M on $26.2M), PP&E at 50-70% (~$2.4-3.3M on $4.8M), intangibles and goodwill at 0% (eliminating $13.1M intangibles net and $19.4M goodwill)—estimated recoverable asset value is approximately $223-230M against $65.7M in face-value liabilities. This yields positive estimated equity recovery of approximately $157-165M, broadly consistent with MFFAIS's reported OLV of $171.4M and LLV of $145.2M. The company holds no revolver borrowings and term loan outstanding principal is $17.6M ($1.5M current, $16.1M noncurrent) at 6.0%, maturing January 2029—a manageable liability against the cash cushion. The key recovery driver is cash: $159.8M represents 52% of total assets and dwarfs the entire liability stack. The critical deterioration since the prior 10-K (December 31, 2025) is concentrated on the income statement and forward cash generation, not balance sheet structure. Q1 2026 net loss was $10.9M versus net income of $7.0M in Q1 2025—a $17.9M swing—driven by Wound Care revenue collapsing 60% YoY to $22.6M following January 1, 2026 Medicare reimbursement changes that reduced skin substitute reimbursement rates and created administrative barriers. Total revenue fell 33% to $59.0M. Operating cash flow compressed to $1.9M from $5.3M, with the company investing $5.0M in the Regen Lab exclusive distribution rights acquisition (booked as intangible, zero liquidation value). A subsequent-event cost reduction initiative announced in April 2026 involves ~15% workforce reduction with ~$4M in Q2 2026 one-time charges. A Town Park lease extension through January 2038 adds $9.8M in undiscounted future rent obligations not yet reflected as a balance sheet lease liability in this filing—the filing discusses the April 2026 lease amendment as a subsequent event and does not separately XBRL-tag the incremental right-of-use asset or lease liability in this 10-Q. The allowance for credit losses grew to $9.5M from $8.7M at year-end 2025 and from $3.9M at Q1 2025, reflecting credit stress in the Wound Care channel post-reimbursement change. Deferred tax asset of $24.1M carries zero liquidation value. Goodwill of $19.4M is not impaired per filing but carries zero recovery. The share-based compensation line ran negative ($-1.7M cash flow adjustment) in Q1 2026 versus positive $4.3M in Q1 2025, driven by PSU award reversals; this does not affect the balance sheet recovery posture.
▼ Community Notes